BioCentury | Jun 18, 2015
Distillery Techniques

Techniques: Crystal structure of myeloid leukemia cell differentiation protein (MCL1)

...inhibitors. (See "Watershed Crystal", page 16) Teva Pharmaceutical Industries Ltd. and Hospira Inc. market Synribo omacetaxine mepesuccinate...
BioCentury | Apr 30, 2015
Distillery Therapeutics

Therapeutics: Myeloid leukemia cell differentiation protein (MCL1); B cell lymphoma 2 (BCL-2; BCL2); Bcl-XL

...cancer cell lines and animal models. Teva Pharmaceutical Industries Ltd. and Hospira Inc. market Synribo omacetaxine mepesuccinate...
BioCentury | May 12, 2014
Clinical News

Synribo omacetaxine mepesuccinate regulatory update

...FDA approved an updated label for Synribo omacetaxine mepesuccinate from Teva to allow home administration of the...
...intolerance to >=2 tyrosine kinase inhibitors (TKIs). Previously, patients had to receive subcutaneous injections of Synribo...
...Petah Tikva, Israel Hospira Inc. (NYSE:HSP), Lake Forest, Ill. Product: Synribo omacetaxine mepesuccinate (formerly Omapro , Ceflatonin...
BioCentury | Apr 7, 2014
Finance

1Q Stock Wrap-Up: Small but mighty

...drug Copaxone glatiramer acetate Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) FDA grants full approval to Synribo omacetaxine mepesuccinate...
...and/or intolerance to two or more tyrosine kinase inhibitors (TKIs). FDA granted accelerated approval to Synribo...
BioCentury | Feb 17, 2014
Clinical News

Synribo omacetaxine mepesuccinate regulatory update

...FDA granted full approval to Teva's Synribo omacetaxine mepesuccinate to treat chronic or accelerated phase chronic myelogenous...
...with resistance and/or intolerance to >=2 tyrosine kinase inhibitors (TKIs). FDA granted accelerated approval to Synribo...
...Petah Tikva, Israel Hospira Inc. (NYSE:HSP), Lake Forest, Ill. Product: Synribo omacetaxine mepesuccinate (formerly Omapro , Ceflatonin...
BioCentury | Feb 14, 2014
Company News

FDA grants full approval to Teva's Synribo

...FDA granted full approval to Synribo omacetaxine mepesuccinate from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) to treat chronic...
...and/or intolerance to two or more tyrosine kinase inhibitors (TKIs). FDA granted accelerated approval to Synribo...
BioCentury | Sep 2, 2013
Strategy

Back to School 2013: Facing reality

For the first time since the 2008 meltdown, nearly everything appears to be coming up roses for biopharma. Money is again flowing into the sector, FDA , EMA and Japan's Pharmaceuticals and Medical Devices Agency are...
BioCentury | Jan 7, 2013
Finance

Buyside View XXI: Sunny side up

...Corp. (TSX:TKM; NASDAQ:TKMR) Marqibo vincristine Philadelphia chromosome-negative ALL U.S. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Synribo omacetaxine mepesuccinate...
BioCentury | Jan 7, 2013
Finance

4Q Stock Wrap-Up: Go big or go home

...in adults and children 6-17 years old Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) FDA approves Synribo omacetaxine mepesuccinate...
BioCentury | Oct 29, 2012
Finance

Highlights of weekly biotech stock moves

...response letter for another. On Friday, FDA granted accelerated approval to an NDA for Synribo omacetaxine mepesuccinate...
Items per page:
1 - 10 of 108